Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk
- PMID: 30251170
- DOI: 10.1007/s10689-018-0104-4
Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk
Abstract
The inclusion of polygenic risk scores in breast cancer risk prediction models provides a more personalised and accurate prediction of breast cancer risk for women with and without breast cancer, who would otherwise receive negative results from traditional testing of moderate- and high-risk genes. This study aimed to develop, and pilot test a leaflet with a sample of women participating in a large prospective cohort study. The leaflet aimed to provide information about polygenic risk to assist women to decide whether or not to learn results from genomic testing for common risk variants associated with breast cancer risk. A prototype of the leaflet was developed based on published literature and with the expertise from a multidisciplinary team. The acceptability of the leaflet was assessed by self-report questionnaire among 29 women participating in the prospective cohort study. More than 80% participants stated that the leaflet was clear, informative and easy to understand and increased their understanding of polygenic risk information. While low to moderate levels of distress/worry were reported around implications of the test results for the next generation, 71% felt reassured and agreed that the information provided in the leaflet had helped them cope. Pilot-test results indicate the leaflet is acceptable to the participants and the revised leaflet can be used as an information tool for women undergoing genomic testing. This educational leaflet will become a useful information source to meet the information needs of women undergoing genomic testing.
Keywords: Breast cancer; Genomic testing; Leaflet; Polygenic risk score.
Similar articles
-
Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study.BMC Cancer. 2017 Jul 18;17(1):491. doi: 10.1186/s12885-017-3485-0. BMC Cancer. 2017. PMID: 28720130 Free PMC article. Clinical Trial.
-
Women's responses and understanding of polygenic breast cancer risk information.Fam Cancer. 2020 Oct;19(4):297-306. doi: 10.1007/s10689-020-00185-2. Fam Cancer. 2020. PMID: 32430685
-
Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk.J Genet Couns. 2018 Sep;27(5):1055-1066. doi: 10.1007/s10897-018-0223-y. Epub 2018 Feb 17. J Genet Couns. 2018. PMID: 29455319
-
A literature review of the psychological impact of genetic testing on breast cancer patients.Patient Educ Couns. 2006 Jul;62(1):13-20. doi: 10.1016/j.pec.2005.08.012. Epub 2005 Oct 19. Patient Educ Couns. 2006. PMID: 16242293 Review.
-
Genetic testing by cancer site: breast.Cancer J. 2012 Jul-Aug;18(4):310-9. doi: 10.1097/PPO.0b013e318260946f. Cancer J. 2012. PMID: 22846731 Review.
Cited by
-
Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test.Public Health Genomics. 2020;23(1-2):6-19. doi: 10.1159/000505854. Epub 2020 Mar 19. Public Health Genomics. 2020. PMID: 32191943 Free PMC article.
-
Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant.Breast. 2021 Dec;60:38-44. doi: 10.1016/j.breast.2021.08.011. Epub 2021 Aug 23. Breast. 2021. PMID: 34455229 Free PMC article.
-
"For and against" factors influencing participation in personalized breast cancer screening programs: a qualitative systematic review until March 2022.Arch Public Health. 2024 Feb 22;82(1):23. doi: 10.1186/s13690-024-01248-x. Arch Public Health. 2024. PMID: 38389068 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical